Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015. ,
Cancer statistics, CA Cancer J Clin, vol.67, issue.1, pp.7-30, 2017. ,
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database, J Clin Oncol, vol.24, issue.28, pp.4539-4583, 2006. ,
Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities, Clin Cancer Res. 1 mai, vol.18, issue.9, pp.2443-51, 2012. ,
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clin Proc, p.11 ,
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update, J Clin Oncol. 15 janv, vol.22, issue.2, pp.330-53, 2003. ,
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line, Curr Oncol. juin, vol.19, issue.1, pp.52-60, 2012. ,
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.33, issue.30, pp.3488-515, 2015. ,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet, avr, vol.387, pp.1415-1441, 2016. ,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017. ,
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med ,
,
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol. 1 févr, vol.4, issue.2, p.210, 2018. ,
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 30 avr, vol.387, pp.1837-1883, 2016. ,
, Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More-The ASCO Post
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 14 juin, vol.378, issue.24, pp.2288-301, 2018. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018. ,
Current state of immunotherapy for non-small cell lung cancer, Transl Lung Cancer Res. avr, vol.6, issue.2, pp.196-211, 2017. ,
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study, Lung Cancer. mai, vol.119, pp.14-20, 2018. ,
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by AntiPD-1/PD-L1, Clin Cancer Res. 15 avr, vol.23, issue.8, pp.1920-1928, 2017. ,
Immunerelated adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016. ,
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. mars, vol.19, issue.2, pp.120-129, 2018. ,
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. 21 mai, vol.372, issue.21, pp.2018-2046, 2015. ,
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis, JCO Precis Oncol, issue.1, pp.1-15, 2017. ,
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 janv, vol.2, issue.1, pp.46-54, 2016. ,
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, issue.6, 2018. ,
,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015. ,
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer, J Clin Oncol. 10 avr, vol.34, issue.11, pp.1223-1253, 2016. ,
Référentiel Rhône Alpes Auvergne, p.57, 2018. ,
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, J Thorac Oncol. 1 août, vol.2, issue.8, pp.706-720, 2007. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer. 1 janv, vol.45, issue.2, pp.228-275, 2009. ,
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions, Cancer Treat Rev. 1 mars, vol.64, pp.21-30, 2018. ,
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis, Clin Respir J, vol.13, issue.2017 ,
,
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in NonSmall Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016. ,
IFCT 1502-CLINIVO : efficacité et tolérance du nivolumab et du traitement post-nivolumab dans le cancer bronchique non à petites cellules au stade avancé. Une étude en vie réelle dans le cadre de l'ATU nivolumab 2015, Rev Mal Respir. janv, vol.35, p.8, 2018. ,
1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ?70 years and with poor performance status, Ann Oncol, issue.1, 2017. ,
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer. janv, vol.115, pp.71-75, 2018. ,
Association of ImmuneRelated Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 mars, vol.4, issue.3, p.374, 2018. ,
The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol. mars, vol.19, issue.3, pp.310-332, 2018. ,
Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.15, issue.2018 ,
,
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02126484
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018. ,
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.104-112, 2018. ,
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1, OncoImmunology. 3 juin, vol.7, issue.6, p.1434468, 2018. ,
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.350, issue.6264, pp.1084-1093, 2015. ,
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell. 9 avr, vol.33, issue.4, pp.570-80, 2018. ,
An obesity-associated gut microbiome with increased capacity for energy harvest | Nature ,
Gut Microbiome and Obesity: A Plausible Explanation for Obesity, Curr Obes Rep. juin, vol.4, issue.2, pp.250-61, 2015. ,
The Gut Microbiome Profile in Obesity: A Systematic Review, Int J Endocrinol, vol.2018, pp.1-9, 2018. ,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev. avr, vol.45, pp.30-37, 2016. ,
01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC), J Thorac Oncol. janv, vol.12, issue.1, p.422, 2017. ,
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01958243
,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015. ,
Cancer statistics, CA Cancer J Clin, vol.67, issue.1, pp.7-30, 2017. ,
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database, J Clin Oncol, vol.24, issue.28, pp.4539-4583, 2006. ,
Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities, Clin Cancer Res. 1 mai, vol.18, issue.9, pp.2443-51, 2012. ,
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clin Proc, p.11 ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017. ,
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med ,
,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016. ,
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017. ,
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, J Clin Oncol. 1 sept, vol.34, issue.25, pp.2980-2987, 2016. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 30 avr, vol.387, pp.1837-1883, 2016. ,
Current state of immunotherapy for non-small cell lung cancer, Transl Lung Cancer Res. avr, vol.6, issue.2, pp.196-211, 2017. ,
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. 21 mai, vol.372, issue.21, pp.2018-2046, 2015. ,
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res. 15 avr, vol.23, issue.8, pp.1920-1928, 2017. ,
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016. ,
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis, JCO Precis Oncol, issue.1, pp.1-15, 2017. ,
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. mars, vol.19, issue.2, pp.120-129, 2018. ,
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 janv, vol.2, issue.1, pp.46-54, 2016. ,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015. ,
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, issue.6, 2018. ,
,
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer, J Clin Oncol. 10 avr, vol.34, issue.11, pp.1223-1253, 2016. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline ,
, Eur J Cancer. 1 janv, vol.45, issue.2, pp.228-275, 2009.
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions, Cancer Treat Rev. 1 mars, vol.64, pp.21-30, 2018. ,
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis, Clin Respir J, vol.13, issue.2017 ,
,
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016. ,
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer. janv, vol.115, pp.71-75, 2018. ,
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 mars, vol.4, issue.3, p.374, 2018. ,
The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol. mars, vol.19, issue.3, pp.310-332, 2018. ,
Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.15, issue.2018 ,
,
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01727917
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018. ,
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science. 05, vol.359, issue.6371, pp.104-112, 2018. ,
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1, OncoImmunology. 3 juin, vol.7, issue.6, p.1434468, 2018. ,
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.350, issue.6264, pp.1084-1093, 2015. ,
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell. 9 avr, vol.33, issue.4, pp.570-80, 2018. ,
An obesity-associated gut microbiome with increased capacity for energy harvest | Nature ,
Gut Microbiome and Obesity: A Plausible Explanation for Obesity, Curr Obes Rep. juin, vol.4, issue.2, pp.250-61, 2015. ,
The Gut Microbiome Profile in Obesity: A Systematic Review, Int J Endocrinol, vol.2018, pp.1-9, 2018. ,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev. avr, vol.45, pp.30-37, 2016. ,
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol. 1 févr, vol.4, issue.2, p.210, 2018. ,
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PDL1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, 2018. ,
,